Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2024-05-14 Capital/Financing Update
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes detailed information about a material definitive agreement related to the issuance of convertible senior notes, including purchase agreements, indenture terms, capped call transactions, repurchases of existing notes, and share repurchases. It also references exhibits and press releases related to these transactions. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, proxy statement, or governance report. It is a regulatory filing announcing significant financing and capital structure updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-05-14 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or changes that shareholders should know about. The text includes details about a material definitive agreement amendment, a proposed offering of convertible senior notes, and related financial obligations. It also references exhibits such as the amendment and a press release. The document does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). Instead, it focuses on financing activities and capital structure changes, specifically a share repurchase program and a convertible notes offering. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The length and detail confirm it is not a brief announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear description of financing transactions and the nature of Form 8-K filings.
2024-05-08 English
10-Q - PCRX - 3.31.2024
Interim / Quarterly Report Q1 2024
2024-05-07 English
8-K
Transaction in Own Shares Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Pacira BioSciences, Inc. It includes an announcement of the company's first quarter financial results via a press release (Exhibit 99.1) and an announcement of a new share repurchase program authorized by the Board of Directors. The document itself does not contain detailed financial statements or comprehensive financial analysis but rather announces the earnings release and the share repurchase program. The share repurchase program announcement fits the category of Transaction in Own Shares (POS). The earnings release is referenced as an exhibit but not included in full text here, so the document is not an Earnings Release (ER) itself. Given the content, the primary classification is Transaction in Own Shares (POS) due to the share repurchase program announcement. Confidence is high as the document clearly states the share repurchase program details under Item 8.01 and the earnings release is only furnished as an exhibit, not the main content.
2024-05-07 English
ARS
Annual Report
2024-04-22 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement related to the company's annual meeting. It includes voting items such as election of directors, ratification of auditors, and advisory approval of executive compensation. The text explicitly states it is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 and is titled 'Definitive Proxy Statement'. This type of document corresponds to the Remuneration Information category (DEF 14A) because it includes executive compensation proposals and other proxy-related matters. The document length is under 5,000 characters and contains detailed proxy voting information, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is DEF 14A with high confidence.
2024-04-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.